![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-desktop-headergif-65408.gif)
![Ofichem Header](https://www.pharmacompass.com/image/flap/ofichem-corp-ad-w31-mobile-headergif-45399.gif)
Active Filter(s):
Details:
The BIOCAD and Shanghai Pharmaceuticals Holding joint venture has announced enrollment of patient with treatment prolgolimab in BCD-100-3/DOMAJOR clinical trial of an original anti-PD1 check point inhibitor in patients with non-small cell lung cancer (NSCLC) by BIOCAD.
Lead Product(s): BCD-100,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: BCD-100
Highest Development Status: Preclinical Product Type: Large molecule
Recipient: Biocad
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021